{
    "id": 22504,
    "fullName": "FAP positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FAP positive indicates the presence of the FAP gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2191,
        "geneSymbol": "FAP",
        "terms": [
            "FAP",
            "DPPIV",
            "FAPA",
            "FAPalpha",
            "SIMP"
        ]
    },
    "variant": "positive",
    "createDate": "05/12/2016",
    "updateDate": "01/16/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6299,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an osteosarcoma cell line xenograft model positive for Fap demonstrated sensitivity to RG7386, resulting in tumor growth inhibition (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6301,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an osteosarcoma patient derived xenograft (PDX) model positive for Fap demonstrated a greater sensitivity to the combination treatment of RG7386 and Adria (doxorubicin) when compared to either treatment alone, resulting in complete tumor remission (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4112,
                "therapyName": "Doxorubicin + RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6283,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell line xenograft models positive for Fap demonstrated sensitivity to RG7386, resulting in repression of tumor growth and apoptotic induction (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6294,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RG7386 treatment of malignant spindle cell melanoma cell line xenograft models positive for Fap resulted in tumor growth inhibition (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 3162,
                "name": "malignant spindle cell melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6286,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of RG7386 and Camptosar (irinotecan) resulted in an additive effect demonstrating decreased tumor burden and a complete tumor response in colorectal cancer xenograft models positive for Fap (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4111,
                "therapyName": "Irinotecan + RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6270,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TNFRSF10B over expressing renal carcinoma cells positive for FAP demonstrated sensitivity to RG7386, resulting in apoptotic induction in culture (PMID: 27037412).",
            "molecularProfile": {
                "id": 23095,
                "profileName": "FAP pos TNFRSF10B over exp"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 4451,
                "name": "renal carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6273,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TNFRSF10B over expressing colorectal cancer cells positive for FAP demonstrated sensitivity to RG7386, resulting in apoptotic induction in culture (PMID: 27037412).",
            "molecularProfile": {
                "id": 23095,
                "profileName": "FAP pos TNFRSF10B over exp"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6276,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TNFRSF10B and FAP positive breast cancer cells demonstrated sensitivity to RG7386, resulting in apoptotic induction in culture (PMID: 27037412).",
            "molecularProfile": {
                "id": 23096,
                "profileName": "FAP pos TNFRSF10B pos"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14969,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, RO6874813 (RG7386) demonstrated safety and efficacy in patients with solid tumors positive for FAP and TNFRSF10B (DR5) (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A092, NCT02558140).",
            "molecularProfile": {
                "id": 23096,
                "profileName": "FAP pos TNFRSF10B pos"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11869,
                    "pubMedId": null,
                    "title": "Phase 1 trial of RO6874813, a novel bispecific FAP-DR5 antibody, in patients with solid tumors",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A092"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6278,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FAP positive lung carcinoma cells with decreased expression of TNFRSF10B demonstrated sensitivity to RG7386, resulting in apoptotic induction in culture (PMID: 27037412).",
            "molecularProfile": {
                "id": 23097,
                "profileName": "FAP pos TNFRSF10B dec exp"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23089,
            "profileName": "FAP positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23095,
            "profileName": "FAP pos TNFRSF10B over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23096,
            "profileName": "FAP pos TNFRSF10B pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23097,
            "profileName": "FAP pos TNFRSF10B dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}